Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Low CD4 count, suboptimal HIV treatment linked to higher anal cancer risk

People with HIV who experienced extensive immune deficiency or who used early antiretroviral drugs before the advent of combination highly-active antiretroviral therapy (HAART) in the mid-90s may be at greater risk for developing anal cancer, according to a retrospective analysis published in the January 28 edition of AIDS.

Published
23 January 2015
From
HIVandHepatitis.com
Starting HIV treatment early and then interrupting is no better than delaying it

A French study that looked at the total amount of time since infection that people with HIV have spent with a detectable viral load has found that,

Published
22 January 2015
By
Gus Cairns
Exploring possible treatment options after virological failure with raltegravir

In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

Published
21 January 2015
From
CATIE
New anti HIV drug dolutegravir is effective at low doses

The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.

Published
21 January 2015
From
MMD Newswire
HIV—Pregnancy-related issues

Themed issue of CATIE's magazine Treatment Update, with several articles on the safety of antiretrovirals during pregnancy.

Published
20 January 2015
From
CATIE
Zimbabwe finally switches away from stavudine

The Zimbabwean government has finally dropped stavudine, lamivudine and nevirapine as its first-line HIV therapy in favour of a single dose treatment which has a combination of three drugs, namely tenofovir/lamivudine/efavirenz (TLN).The Government dropped the first line HIV treatment after realizing that it was causing severe side effects on patients. Stanley Takaona of the Zimbabwe HIV and AIDS Activist Union Community Trust said the introduction of the new HIV drug was going to save more lives.

Published
19 January 2015
From
AllAfrica
Dramatic decline in risk for heart attacks among HIV-positive Kaiser Permanente members

Previously reported increased risk of heart attacks among HIV-positive individuals has been largely reversed in recent years for Kaiser Permanente's California patients, according to a study published in the current online issue of Clinical Infectious Diseases. The adjusted risk ratio for heart attacks among HIV-positive study participants went from an 80 percent increased risk in 1996 to no increased risk in 2010-2011. Reported first on Aidsmap at http://www.aidsmap.com/Heart-attack-risk-in-people-with-HIV-may-be-falling-but-not-in-women/page/2834402/ .

Published
19 January 2015
From
Eurekalert
Drug Resistance, While Rare, Can Occur After Contracting HIV on PrEP

For the first time, a study has shown that, although rare, resistance to Truvada can develop if someone contracts HIV while taking the drug as PrEP.

Published
16 January 2015
From
AIDSMeds
Hepatitis C drug delayed by NHS due to high cost

The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.

Published
16 January 2015
From
The Guardian
Janssen launches HIV combo Rezolsta in UK

Johnson & Johnson unit Janssen has launched its once-daily, fixed-dose HIV combination therapy Rezolsta in the UK.

 Rezolsta combines the company’s big-selling HIV therapy Prezista (darunavir) and Gilead Science’s Tybost (cobicistat).

Published
15 January 2015
From
Pharma Times
← First12345...376Next →

Filter by country